You are here

AbbVie

Big pharma freshens up

Big pharma freshens up

EP Vantage

Bristol Myers Squibb

Flag link:

Series of JAK inhibitor delays may signal an upcoming FDA adcomm

Series of JAK inhibitor delays may signal an upcoming FDA adcomm

Endpoints

Flag link:

AbbVie presents applications to FDA and EMA for approval of SKYRIZI in psoriatic arthritis

AbbVie presents applications to FDA and EMA for approval of SKYRIZI in psoriatic arthritis

Pharmaceutical Business Review

psoriatic arthritis

Flag link:

AbbVie's Rinvoq expansion hits a 2nd snag as FDA delays $2B atopic dermatitis ruling

AbbVie's Rinvoq expansion hits a 2nd snag as FDA delays $2B atopic dermatitis ruling

Fierce Pharma

Flag link:

AbbVie Receives NDA for Atogepant, Aims to Stop Migraines in Their Tracks

AbbVie Receives NDA for Atogepant, Aims to Stop Migraines in Their Tracks

BioSpace

Flag link:

AbbVie accuses rival of stealing blockbuster ‘trade secrets’ as clock ticks down on biosimilar assault

AbbVie accuses rival of stealing blockbuster ‘trade secrets’ as clock ticks down on biosimilar assault

Endpoints

Flag link:

13 leading drugmakers' top 3 drugs by revenue in 2020

13 leading drugmakers' top 3 drugs by revenue in 2020

Beckers Hospital Review

Flag link:

AbbVie's approval delay raises further concerns about JAK drugs

AbbVie's approval delay raises further concerns about JAK drugs

BioPharma Dive

rheumatoid arthritis

Flag link:

Horizon, Roche's Genentech, AbbVie and Neurocrine rank as top pharma places to work in annual poll

Horizon, Roche's Genentech, AbbVie and Neurocrine rank as top pharma places to work in annual poll

Fierce Pharma

Horizon Therapeutics

employee satisfaction

Flag link:

4 Pharma Stocks That Could Be Losers With the $1.9 Trillion Stimulus Package

4 Pharma Stocks That Could Be Losers With the $1.9 Trillion Stimulus Package

Motley Fool

Jazz Pharmaceuticals

Flag link:

AbbVie looks to shed Allergan's legacy women's health unit as it hunkers down for Humira biosim doomsday — report

AbbVie looks to shed Allergan's legacy women's health unit as it hunkers down for Humira biosim doomsday — report

Endpoints

Flag link:

AbbVie to Fund Mitokinin's Parkinson Research with Option to Buy

AbbVie to Fund Mitokinin's Parkinson Research with Option to Buy

BioSpace

Parkinson's Disease

Flag link:

AbbVie sells biologics plant to Pharmaron, fueling the China company's cell and gene therapy ambitions

AbbVie sells biologics plant to Pharmaron, fueling the China company's cell and gene therapy ambitions

Fierce Pharma

drug manufacturing

Flag link:

AbbVie puts an end to Botox trade secrets suit, imposes royalty, license deal on competitor Evolus

AbbVie puts an end to Botox trade secrets suit, imposes royalty, license deal on competitor Evolus

Endpoints

Flag link:

AbbVie adds to the Botox war chest with a 12th FDA approval — but competition is fast approaching

AbbVie adds to the Botox war chest with a 12th FDA approval — but competition is fast approaching

Endpoints

bladder muscle overactivity

Flag link:

After ditching Editas, AbbVie taps Caribou for new CRISPR, CAR-T pact

After ditching Editas, AbbVie taps Caribou for new CRISPR, CAR-T pact

Fierce Biotech

Editas Medicine

Caribou Biosciences

Flag link:

AbbVie's immunology newbies Skyrizi and Rinvoq pick up the slack from declining Humira, but safety questions dog execs

AbbVie's immunology newbies Skyrizi and Rinvoq pick up the slack from declining Humira, but safety questions dog execs

Fierce Pharma

Flag link:

AZ says Calquence is a safer drug than Imbruvica

AZ says Calquence is a safer drug than Imbruvica

Pharmaforum

Flag link:

Pharma TV ad spenders blow up December with spendiest month of 2020

Pharma TV ad spenders blow up December with spendiest month of 2020

Fierce Pharma

Flag link:

AbbVie eyes Humira matching move into psoriatic arthritis for immunology follow-up Skyrizi

AbbVie eyes Humira matching move into psoriatic arthritis for immunology follow-up Skyrizi

Endpoints

psoriatic arthritis

Flag link:

Pages